Long-lasting response with lapatinib treatment: a case report

Risposta persistente in corso di trattamento con lapatinib: un caso clinico

Authors

  • Andrea Milani Divisione di Oncologia Clinica Investigativa (INCO), Candiolo Cancer Institute-FPO-IRCCS, Candiolo, Torino (Italy)
  • Imperia Nuzzolese Divisione di Oncologia Medica-1, Candiolo Cancer Institute-FPO-IRCCS, Candiolo, Torino and Dipartimento di Oncologia, Università di Torino (Italy)
  • Giovanna Chilà Divisione di Oncologia Medica-1, Candiolo Cancer Institute-FPO-IRCCS, Candiolo, Torino and Dipartimento di Oncologia, Università di Torino, Torino (Italy)

DOI:

https://doi.org/10.19156/abtpn.2018.0030

Keywords:

Lapatinib, metastatic breast cancer, brain metastasis, HER2

Abstract

Lapatinib is a small molecule and a reversible inhibitor of HER2, which has shown to be effective on brain lesions in patients with HER2-positive breast cancer relapsed at the central nervous system (CNS). We report the clinical case of a young woman, treated with the combination of lapatinib and capecitabine from September 2009 to today for a metastatic recurrence of HER2-positive breast carcinoma at CNS level and who has achieved a complete response of the encephalic lesion and has not shown disease progression at systemic or CNS level, with excellent tolerance profile (Oncology).

Downloads

Download data is not yet available.

Downloads

Published

2018-09-10

How to Cite

Milani, A., Nuzzolese, I., & Chilà, G. (2018). Long-lasting response with lapatinib treatment: a case report: Risposta persistente in corso di trattamento con lapatinib: un caso clinico. AboutOpen, 4(1), 1–4. https://doi.org/10.19156/abtpn.2018.0030

Metrics